FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer
26 Mar, 2021 | 08:30h | UTC
Commentary on Twitter
Our paper published today in @NatRevClinOncol discussing the dropping of bar for approval of cancer drugs. These two examples highlight why we all should seriously be concerned about this low bar. https://t.co/T27QI00dj2 pic.twitter.com/26Df3fJsoD
— Bishal Gyawali (@oncology_bg) March 25, 2021